Overview

This is a disease that is transmitted from mosquitoes to humans and affects many people in the world. Found in densely populated countries and continents, like Africa, Asia and the tropics of the Americas, this has severe symptoms. This viral disease is caused by the Chikungunya virus of the Togaviridae. First identified in the United Republic of Tanzania in 1952 and subsequently in other countries like Africa and Asia. Since 2004 the outbreak of CHIKV virus has become more widespread and caused partly due to the viral adaptations allowing the virus to be spread more easily by Aedes albopictus mosquitoes. The transmission has been noted to persist in countries where there is a large population, but interestingly, the transmission has been interrupted on islands where a high proportion of the population is infected and then immune.

Symptoms

The onset of the disease is usually in 4-8 days and after a bite of an infected mosquitoes, it is characterized by an abrupt onset of fever and then joint pain. This joint pain is severed and lasts for a few days but may prolong for months maybe even years. Other signs are joint swelling, muscle pains, headache, nausea, fatigue and rash. These symptoms also overlap with those of dengue and Zika virus and can be misdiagnosed. Most people fully recover from the infection and experience only mild and sometimes the infection even goes unrecognized. However, there have been cases of eye, heart, and neurological complications. The elderly and newborns are more susceptible to the infection and if they have any underlying conditions then they are likely to become severely ill increasing the risk of death.

Diagnosis and treatment

The diagnosis and treatment of the virus may be done by blood sampling and other tests like reverse transcriptase–polymerase chain reaction (RT–PCR). Other tests detect the activity of the antibodies. These can be detected in the first week after illness onset and can be detected for about 2 months. Many clinical measures can be taken to address fever and joint pain. But there is no specific anti-viral drug treatment for the virus.

Preventing Chikungunya

As this disease is caused by the bite of a mosquito, you must reduce the opportunities to let the mosquito breed. Mosquitoes bite during the day and night, and for people who live in risk areas like southeast Asia, Africa and tropical regions of America, many outbreaks happen each year. The best way to prevent it is to protect yourself from the mosquito's bite. You also must get vaccinated before travelling to any of these regions. Use insect repellent, and wear long-sleeved shirts and pants. You can also treat your clothes and gear with permethrin. As we all know, they tend to breed in humid places and places where they have access to water, so try to close the rooms that are air-conditioned with screens and windows. Use nets and mosquito repellents if you are sleeping outside. There are many different types of mosquito repellents like paper, liquid etc, and they are quite effective. If your job needs, you to be stationary for long hours or frequently go outside you must take the necessary precautions.

As we grow older, it is almost expected that memory will fade. Names slip. Dates blur. Thoughts take longer to form. Inside the aging brain, proteins can misfold and clump together, damaging cells and gradually eroding cognition. But not everyone follows this script.

Some people reach their 80s with memory and mental sharpness that rival those decades younger. Scientists call them “super-agers.” Now, new research published in Nature offers a possible explanation for why some brains hold up so remarkably well.

At the heart of the findings lies one of neuroscience’s most contested questions: can adult human brains grow new neurons?

Read: A Longevity Expert Who Studies 'Super Agers' Eats All THIS In A Day

Can The Aging Brain Grow New Cells?

For years, scientists have debated whether neurogenesis, the birth of new neurons, continues into adulthood. While it is well established in babies and young children, and in many animal species, evidence in adult humans has been mixed.

This new study adds weight to the idea that it does continue, even into advanced age.

Researchers examined brain tissue donated after death from several groups: younger adults with normal cognition, older adults with typical memory for their age, people with mild cognitive impairment, individuals with Alzheimer’s disease, and super-agers over 80 whose memory functioned like someone about 30 years younger.

They focused on the hippocampus, the brain’s memory hub and a region long suspected to be a birthplace for new neurons.

To detect neurogenesis, scientists looked for three types of cells: neural stem cells, neuroblasts, and immature neurons. In simple terms, stem cells are like infants, neuroblasts are adolescents, and immature neurons are on the brink of adulthood.

“We identified genetic markers for three key types of cells,” the researchers explained, tracing the pathway from stem cell to developing neuron.

What Makes Super-Agers Different

All groups showed signs of these cell types. The difference lay in the numbers.

Super-agers had roughly twice as many new neurons as older adults with typical memory, and about two and a half times more than those with Alzheimer’s disease. In fact, their hippocampi contained even more immature neurons than the brains of younger adults.

“This paper shows biological proof that the aging brain is plastic,” Tamar Gefen told The New York Times. She added that this adaptability appears to persist “even into a person’s 80s.”

The immature neurons in super-agers also carried distinctive genetic and epigenetic signatures. According to Gefen, as quoted by The New York Times, “Super-aging happens not only because there’s more of these young cells, but because there is a type of genetic programming” that allows them to survive and resist age-related decline.

In other words, it is not just about quantity. It may also be about resilience.

A Clue For Alzheimer’s Disease?

The Alzheimer’s findings were equally intriguing.

People with Alzheimer’s actually had more neural stem cells than other older adults. But they had far fewer neuroblasts and immature neurons. This suggests that while the starting material was present, the developmental process stalled.

One interpretation is that neurogenesis becomes disrupted in Alzheimer’s. Stem cells may remain dormant, unable to mature into functioning neurons.

“If that’s true, that’s really opened up a new direction for the field,” Hongjun Song told The New York Times, suggesting that reactivating these dormant cells could one day become a therapeutic strategy.

It is an exciting possibility. Instead of only trying to prevent damage, scientists might be able to encourage regeneration.

Not Everyone Is Convinced

The neurogenesis debate is far from settled.

Some researchers argue that methodological differences have led to conflicting conclusions over the years. Shawn Sorrells, who studies neurogenesis, told The New York Times that mapping how the hippocampus changes in people who age differently is “fantastically interesting and important,” but he cautioned that the findings should be validated using additional techniques.

Skepticism remains because detecting new neurons in adult human brains is technically difficult. Results often hinge on the markers and imaging tools used.

What This Means For The Future

Even if this study does not end the debate, it opens new doors. If certain people naturally maintain robust neurogenesis into their 80s, researchers want to understand why. Is it genetics? Lifestyle? A combination of both?

Scientists are now exploring whether the special properties seen in super-agers’ immature neurons can be replicated or supported through medication or other interventions.

The bigger takeaway is hopeful. Aging does not necessarily mean inevitable cognitive collapse. The brain may retain more capacity for renewal than once believed.

If neurogenesis truly persists across the lifespan, the story of brain aging may need rewriting. Instead of focusing only on decline, researchers may increasingly look toward regeneration and resilience.

And for anyone worried about forgetting where they left their keys, that possibility feels quietly revolutionary.

In 2025, Andhra Pradesh reported 1,566 scrub typhus cases, and nine suspected deaths, according to data from the Integrated Health Information Platform, Integrated Disease Surveillance Programme (IDSP-IHIP) on 8 December. Followed by Karnataka with 1,870 cases, Tamil Nadu 7,308 cases, and Telangana, 309 cases. Scrub typhus cases have significantly increased from previous year. It is one of the deadliest infections affecting multiple organs, or even death. Early it was relevant to poeple working in fields, new studies show it migrating to human settlements.

What Is Scrub Typhus?

Scrub typhus, also known as bush typhus, is a bacterial infection caused by bacteria infection, caused by bacterium Orientia tsutsugamushi. It is spread through bites of infected larval mites, Chiggers.

Most cases of scrub typhus occur in rural areas of Southeast Asia, Indonesia, China, Japan, the Indian subcontinent and northern Australia. Until now, it was believed that chiggers only lurked in the tall grasses of remote paddy fields or dense forests. Due to this, it is commonly known as "farmers' disease", only confined to the fields.

However, new PLOS study data revealed the opposite. The study is led by researchers from Christian Medical College (CMC) Vellore and international collaborators and suggests that the bulk of infections are now even occurring within human settlements.

The study monitored over 32 000 people in Tamil Nadu, which led to the conclusion that agricultural activities, long considered the primary risk factor, were only weakly associated with the disease in high-prevalence areas.

How are Human Settlements A Prime Factor?

Risk for scrub typhus is significantly higher for those living in clustered houses or homes with fewer rooms. If the micro environment around the residence is unmaintained, gardens are patched, or even the damp corners of a courtyard, it could lead to breeding ground for the mites and the rodents that carry Chiggers.

Who Is At Most Risk?

It was once believed that working-age men were the most affected, but the new study tells otherwise. According to the new data, women over 60 are at the highest risk of infection.

As women spend most of their time in and around the home, due to household work, from the kitchen to the laundry, these activities are now the primary cross point of contact with infected mites.

What Is the Risk Factor Of Infection?

As initial symptoms of infection, such as fever, headache, and muscle pain, are the same as viral flu or dengue, many first seek help from untrained practitioners or local pharmacies.

By the time they reach the hospital, the disease has already progressed to severe complications like acute respiratory distress syndrome (ARDS), Kidney failure, or Meningoencephalitis, which is inflammation of your meninges and brain at the same time, a life-threatening condition.

Not only this, the researchers revealed that nearly 10 percent of affected households exceed 25 percent of their income in the treatment.

For severe cases, the cost of treatment can be up to approximately INR 110,000, a staggering sum for rural and peri-urban families earning a fraction of that monthly.

Prevention

• Do not let the grass grow tall around your house
• Tightly maintain kitchen gardens and remove piles of wood or debris where rodents (the primary hosts for mites) might nest.
• As chiggers are usually found close to the ground, do not sit directly on the grass or soil. Use chairs or mats. For children, make them wear socks and full- length trousers while playing in the yard.
• If you notice a small, dark, cigarette-burn-like mark, it is usually left behind by mites. It is most likely "Eschar". It is an important critical clue. As the bite is painless, it often goes unnoticed.
• Do a thorough skin check for an eschar, especially in warm, moist areas like the armpits, groin, or behind the knees.

Early intervention is necessary, as if a fever lasts more than two days, don't just treat it as "seasonal fever".

Consult a qualified doctor and specifically ask about scrub typhus. Infection can be treated with doxycycline common antibiotic, in the early stages. The case fatality rate in this study was 1.5 percent, hospital based studies in South India have previously recorded mortality rates as high 30 percent when treatment is delayed

The World Health Organization (WHO) recommended that vaccine manufacturers must completely change the three viral strains included in the vaccines for the Northern Hemisphere's next influenza season. This is in the backdrop of the new strain called the influenza A (H3N2) or the subclade k, also known as the super flu. This flu season's vaccine was manufactured before the new strain was detected, which is why there was a mismatch. However, this does not mean that the vaccine was ineffective. In order to achieve better immunization, the WHO has asked manufacturer to consider the viral strain for newer vaccines.

The United States also saw a hike in the numbers of flu patients, including hospitalization. As per the Centers for Disease Control and Prevention or the CDC data, the country saw a 48 per cent hospitalization increase in every week.

However, with the US exiting out of the WHO could be a hurdle for the US Foods and Drugs Administration or the FDA to approve the WHO updates. Furthermore, the vaccine overhaul too have removed influenza vaccine from the mandatory coverage.

What Does The New WHO Influenza Vaccine Mean For The US?

The latest flu vaccine recommendations from the World Health Organization come at a politically sensitive moment. They are the first issued since the United States formally withdrew from WHO on January 22. The US has long been one of WHO’s largest contributors, providing more than $680 million annually in recent years, according to the Department of Health and Human Services.

Despite the withdrawal, NPR reported that scientists from the Centers for Disease Control and Prevention attended the strain selection meeting virtually. The gathering took place in Istanbul, Turkey.

Daniel Jernigan, former head of the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, said the newly announced vaccine composition underscores why continued engagement with WHO is essential. He noted that flu prevention depends on global cooperation. Through WHO’s network, the CDC gains access to virus samples from around the world, while WHO-affiliated labs benefit from the CDC’s specialized testing capabilities. According to him, the collaboration strengthens both sides.

Concerns had surfaced about how the US exit might disrupt flu vaccine production. Andrew Pekosz, a professor at the Johns Hopkins Bloomberg School of Public Health, acknowledged that many researchers were worried about potential ripple effects.

However, two of the strains selected for next fall’s flu vaccines are based on virus samples collected in Missouri and Pennsylvania. That detail suggests that US scientists remain actively involved in surveillance and strain identification. Jernigan pointed out that this is particularly important for improving protection against recently circulating flu B viruses, especially in children. He added that if the CDC were ever prevented from participating in WHO’s network, both the US and international partners would lose valuable data and expertise.

Pekosz explained that the global flu monitoring system was intentionally designed with redundancy. Independent laboratories worldwide collect and analyze viral samples before submitting them to centralized databases. Multiple facilities can grow and test these viruses, ensuring backup capacity if one lab encounters problems. This structure helps safeguard vaccine development from single-point failures.

Danuta Skowronski, MD, a flu researcher at the British Columbia Centre for Disease Control in western Canada, emphasized that these lab networks enable researchers to monitor the genetic makeup of circulating viruses in near real time. Academic centers and vaccine effectiveness networks also contribute data, reinforcing the global surveillance web.

Countries typically look to WHO guidance when deciding their own vaccine formulations. In the United States, the Food and Drug Administration has historically aligned its recommendations with WHO’s selections. The FDA’s Vaccines and Related Biological Products Advisory Committee is scheduled to meet March 12 to discuss upcoming flu shot recommendations.

Still, uncertainty remains over how US regulators will proceed. Jernigan questioned whether the FDA will follow WHO’s updates without introducing additional hurdles for manufacturers preparing this fall’s vaccines.

Over the past year, several public health decisions have surprised experts, including shifts in vaccine-related policies. Earlier this month, the FDA initially declined to consider Moderna’s mRNA flu vaccine, a technology that could potentially reduce production time from six months to as little as six to eight weeks. Such speed could allow manufacturers to respond more quickly to late-emerging viral strains. The agency reversed that decision a week later.

Further uncertainty surrounds Health and Human Services Secretary Robert F. Kennedy Jr., who has previously expressed skepticism about vaccines. He has made claims linking flu shots to his own spasmodic dysphonia, though there is no scientific evidence supporting that assertion.

Against this backdrop, experts stress that global coordination remains central to effective influenza prevention, regardless of shifting political landscapes.